Phaseline

Targets › PVRIG

PVRIG (Transmembrane protein PVRIG): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Sep 2027.

Cell surface receptor for NECTIN2. May act as a coinhibitory receptor that suppresses T-cell receptor-mediated signals. (UniProt, Q6DKI7)

Open in Phaseline: the race on PVRIG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Hefei TG ImmunoPharma Co., Ltd.NM1F Injection
Anti-PVRIG monoclonal antibody
PVRIGPhase 1Ovarian CancerSep 2027
D3 Bio (Wuxi)D3L-002
Bispecific antibody targeting TIGIT and PVRIG
TIGIT, PVRIGPhase 1Advanced Solid TumorNov 2027

Conditions

Advanced Solid Tumor (1) Ovarian Cancer (1)

Modalities

small molecule (1), mixed (1)

Companies

D3 Bio (Wuxi) (1) Hefei TG ImmunoPharma Co., Ltd. (1)

Related targets

TIGIT (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.